Cytel has entered into a three-year strategic agreement to expand GSK‘s deployment of clinical strategy platform Solara. This collaboration will provide critical input to future development of the Solara platform.The platform has the potential to enable GSK to efficiently align on trial goals, navigate trial uncertainties and produce pressure-tested clinical trial designs that minimize costs and accelerate speed to market.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GSK:
- GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
- Akebia should update on vadadustat FDA process in next month, says Piper Sandler
- GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysis
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
- GSK sees FY23 adjusted EPS up 12%-15%, adjusted operating profit up 10%-12%
